First Ever Albumin Diabetes Monitoring Device Patented
Epinex Diagnostics Inc. were recently given a patent from the United States Patent and Trademark Office (USPTO) for the G1A Rapid Diabetes Monitoring Index Test. The revolutionary diabetes monitoring technology could redefine today's current and more invasive ways of testing blood glucose levels. The patent (US7659107B2) is the first rapid glycated albumin test and instrument to be created for potential home and physician's office use.
Albumin has many functions in our blood stream. The beginning stages of diabetic kidney disease removes too much albumin from the blood, which causes small amounts of it to escape through urine (called microalbuminuria). A non-diabetic person typically has 25 milligrams of albumin in their urine everyday. Diabetics of 5 years or more are likely to have 30 to 300 milligrams of albumin in their urine.
Since standard urine dipstick tests for protein are insufficient ways of checking for microalbuminaria, a specific laboratory test is done. The results can reveal whether that person's blood sugar is being controlled properly or not, either by natural insulin releases or diabetes treatment drugs. The new G1A Rapid Diabetes Monitoring Index Test measures the glycated albumin and total albumin in a “more robust” and “more accurate” way through only a pinprick of blood.
HbA1c testing is done every 4-6 months and regular blood glucose testing is done multiple times in a single day, all of these are still considered 95 percent ineffective. "Doctors will no longer have to wait 4-6 months to see if treatments are working," stated Asad Zaidi, Epinex's CEO. "The G1A™ test will allow doctors and patients to adjust their therapeutic and lifestyle interventions on a monthly basis instead."
Diabetes is effecting millions of people worldwide. Estimates are currently showing diabetes is going to double by 2020 because of the rising rate of obesity. Prevention is certainly at the forefront of diabetes research and methods including gastric bypass surgery are being offered to people who might be at risk for developing diabetes. Either way, prevention research must also by followed by diabetes treatment drugs and monitoring devices.
“Epinex Diagnostics was founded in 2002 by three pioneers in the biomedical device industry with a combined experience of more than 70 years in biomedical engineering, product design and development, and medical device marketing. They have been joined by an advisory board of distinguished scientists, experts in marketing and management, and leaders in the field of diabetic care.” (Epinex Diagnostics Inc.)